IKCC voice on the NCI Renal Task Force

As of December 2016, there are now TWO patient advocates on the NCI Renal Task Force.

The US National Cancer Institute’s Renal Task Force is an advisory group that involves the renal oncology community to address the design and prioritization of NCI funded phase 2 and phase 3 clinical trials in renal cell cancer.
https://www.cancer.gov/about-nci/organization/ccct/steering-committees/nctn/genitourinary

Deb Maskens joins the Task Force as a Patient Advocate from the IKCC (International Kidney

read more

KCCure to award large research grant

by Susan Poteat and Hans Hammers, M.D.

KCCure is pleased to announce an inaugural Request for Applications for a $100,000 Grant Award to fund innovative high-risk, high-impact ideas for kidney cancer research.  The application deadline is March 15, 2017.  The grant will be awarded in April 2017, and funding will cover a research project for a two year period.  Investigators representing academic research centers within the United States are eligible to apply.

Proposed projects should develop

read more

Sonepcizumab shows promise for metastatic kidney cancer

Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). However, despite the modest PFS (mean of 2.2 months), the encouraging overall survival warrant further investigation of sonepcizumab in combination with immunotherapies and vascular endothelial growth factor (VEGF) inhibitors. <a href="http://www.healio.com/hematology-oncology/genitourinary-cancer/news/in-the-journals/%7B8d65ed95-3a09-4f92-bd0e-1487c53a7d19%7D/sonepcizumab-shows-promise-for-metastatic-renal-cell-carcinoma

read more